A Reappraisal of Topical Steroid Potency
- 1 May 1996
- journal article
- review article
- Published by Wiley in Pediatric Dermatology
- Vol. 13 (3) , 239-245
- https://doi.org/10.1111/j.1525-1470.1996.tb01211.x
Abstract
Topical corticosteroids have been one of the cornerstones of dermatologic treatment for nearly 40 years. At present the most widely used topical steroid ranking system is the vasoconstrictor assay. To determine whether this is a satisfactory measure of the agents' potency in clinical settings, we examined rankings from the published literature achieved by four different methods: vasoconstriction, clinical outcome, therapeutic index (a ratio of efficacy to systemic safety), and cost, safety, and efficacy. Overall clinical outcome (efficacy) rankings in this study corresponded in only 11 (62%) of 17 topical steroid preparations with the expected vasoconstrictor rankings. The therapeutic index rankings did not correspond with the clinical outcome (33%) or the vasoconstrictor assay (33%) rankings. It was difficult to compare studies because of lack of standardization of clinical trials. We urge that topical steroid rankings not be based solely on vasoconstrictor assays, and that a standard method be developed for clinical trials of the drugs to allow for comparison among preparations.Keywords
This publication has 43 references indexed in Scilit:
- A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatosesJournal of the American Academy of Dermatology, 1991
- A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicusJournal of the American Academy of Dermatology, 1991
- A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasisJournal of the American Academy of Dermatology, 1991
- Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: Report on two double-blind, vehicle-controlled studiesJournal of the American Academy of Dermatology, 1991
- A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1 % diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicusJournal of the American Academy of Dermatology, 1991
- A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1 betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasisJournal of the American Academy of Dermatology, 1991
- A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasisJournal of the American Academy of Dermatology, 1991
- Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitisJournal of the American Academy of Dermatology, 1991
- A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasisJournal of the American Academy of Dermatology, 1991
- Superpotent topical steroid treatment of psoriasis vulgaris—clinical efficacy and adrenal functionJournal of the American Academy of Dermatology, 1987